Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4Other hematologic neoplasm 2Lymphoid 2Sarcoma 1Genitourinary 1

Conditions

Multiple Myeloma 4Neoplasms, Plasma Cell 1

Interventions

Dexamethasone 293Lenalidomide 162Bortezomib 160Cyclophosphamide 121Calcium Dobesilate 118Melphalan 116fludarabine phosphate 75carfilzomib 62pomalidomide 57Whole-Body Irradiation 57Mycophenolic Acid 56Granulocyte Colony-Stimulating Factor 55Peripheral Blood Stem Cell Transplantation 54Filgrastim 54fludarabine 50daratumumab 50Tacrolimus 45Busulfan 45ixazomib 42Thalidomide 37Cyclosporine 32Stem Cell Transplantation 29dexamethasone acetate 28Antilymphocyte Serum 26dexamethasone 21-phosphate 23plerixafor 21elotuzumab 20auricularum 20belantamab mafodotin 19Prednisone 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × plitidepsin × Plasma cell × Clear all
NCT03117361 2020-12-02

Trial of Plitidepsin (AplidinĀ®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide

PharmaMar

Phase 2 Terminated
10 enrolled 37 charts
Plasma cell

Multiple Myeloma

NCT01102426 2020-11-10

ADMYRE

PharmaMar

Phase 3 Completed
255 enrolled 32 charts
Plasma cell

Multiple Myeloma

NCT02100657 2020-10-12

Study of Plitidepsin (AplidinĀ®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma

PharmaMar

Phase 1 Completed
39 enrolled 30 charts
Plasma cell

Multiple Myeloma

NCT00229203 2009-12-24

A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma

PharmaMar

Phase 2 Completed
51 enrolled 10 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚔